Akebia Therapeutics (AKBA) Misses Q3 EPS by 2c

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.47), $0.02 worse than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance